Skip to content
★ Sign in to follow
CS

China Shineway Pharmaceutical Group Ltd. Stock: price and insider trades · Hong Kong

HK·Mcap HK$5.6BHealth Care

No insider purchase over the last 90 days. The latest, by XU SHENG, was filed 19 Dec 2018.

China Shineway Pharmaceutical Group Ltd.: what insiders have been doing

China Shineway Pharmaceutical Group Ltd. is a Health Care company. Its directors and officers file their transactions with HKEX. No insider at China Shineway Pharmaceutical Group Ltd. has published a filing in the past twelve months. The most recent one dates from 31 October 2022.

Our records for China Shineway Pharmaceutical Group Ltd. go back to 2017, with 18 purchases and 2 sales on the open market in total.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.

Insider Decl.
22
Thresholds
n/a
Buy Volume
€3M
18 ops. · all time
Sell Volume
n/a
2 ops. · all time

Since the insiders bought

  • Filed 15 Dec 2017 · 3250 days ago · €54k
    +17.1%
    Entry HK$7.12 · Close at T+365 HK$8.34
  • Filed 24 Nov 2017 · 3271 days ago · €200k
    +40.9%
    Entry HK$7.07 · Close at T+365 HK$9.96

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 295 of 26,897 companies
87.1
score / 100
Value
92
Quality
82
FCF yld17%
Earn yld17%
EV/EBITDA4.4x
ROE10%
Gross mgn72%
Net mgn30%
Debt/EBITDA0.2x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$7.44
Analyst consensus
1 analysts
·
HK$8.57Target HK$8.57(+15%)HK$8.57
Income statement
RevenueHK$3.1B
Gross profitHK$2.3B72% margin
EBITDAHK$1.3B43% margin
Net incomeHK$949.9M30.2% margin
Valuation
PER (trailing)6.3x
PER (forward)6.9x
P/Book0.6x
Beta0.68
Balance sheet & cash
Market capHK$5.6B
Total debtHK$334.9M
Free Cash FlowHK$974.1M
Debt / Equity4%
Profitability & ownership
ROE10.0%
ROA3.9%
% insiders66.3%
% institutions4.9%
Last declaration on 31 October 2022
Declarations22 total
  • ●
    DirectorExecutives
    0HKEX
    280,000 sharesShareXHKGHKEX:DA20221031E00120
  • ▼
    DirectorExecutives
    0HKEX
    1,000,000 sharesShareXHKGHKEX:DA20200320E00164
  • ●
    DirectorExecutives
    0HKEX
    2,000,000 sharesShareXHKGHKEX:DA20190702E00368
  • ▲
    DirectorExecutives
    0HKEX
    2,000,000 sharesShareXHKGHKEX:DA20181219E00279
    Canonical exit: 17 Mar 2019 (T+90)
  • ▲
    DirectorExecutives
    496,141 HKD23HKEX
    71,000 shares@ HK$6.98792.2% of flowShareXHKGHKEX:DA20171215E00153
    Canonical exit: 12 Mar 2018 (T+90)
  • ▲
    DirectorExecutives
    356,898 HKD23HKEX
    51,000 shares@ HK$6.9981.5% of flowShareXHKGHKEX:DA20171215E00154
    Canonical exit: 14 Mar 2018 (T+90)
  • ▲
    DirectorExecutives
    1M HKD24HKEX
    210,000 shares@ HK$6.9876.4% of flowShareXHKGHKEX:DA20171212E00228
    Canonical exit: 11 Mar 2018 (T+90)
  • ▲
    DirectorExecutives
    3M HKD24HKEX
    447,000 shares@ HK$6.862513.3% of flowShareXHKGHKEX:DA20171212E00227
    Canonical exit: 8 Mar 2018 (T+90)
  • ▲
    DirectorExecutives
    141,000 HKD0HKEX
    20,000 shares@ HK$7.051.9% of flowShareXHKGHKEX:DA20171207E00308
    Canonical exit: 5 Mar 2018 (T+90)
  • ▼
    DirectorExecutives
    0HKEX
    20,000 sharesShareXHKGHKEX:DA20171207E00309
  • ▲
    DirectorExecutives
    2M HKD14HKEX
    262,000 shares@ HK$7.053925.1% of flowShareXHKGHKEX:DA20171124E00212
    Canonical exit: 21 Feb 2018 (T+90)
  • ▲
    DirectorExecutives
    1M HKD13HKEX
    188,000 shares@ HK$7.084918.0% of flowShareXHKGHKEX:DA20171124E00213
    Canonical exit: 22 Feb 2018 (T+90)
  • ▲
    DirectorExecutives
    775,709 HKD12HKEX
    110,000 shares@ HK$7.051910.6% of flowShareXHKGHKEX:DA20171123E00197
    Canonical exit: 20 Feb 2018 (T+90)
  • ▲
    DirectorExecutives
    2M HKD14HKEX
    280,000 shares@ HK$7.043626.9% of flowShareXHKGHKEX:DA20171123E00196
    Canonical exit: 19 Feb 2018 (T+90)
  • ▲
    DirectorExecutives
    1M HKD13HKEX
    180,000 shares@ HK$7.111717.5% of flowShareXHKGHKEX:DA20171123E00195
    Canonical exit: 18 Feb 2018 (T+90)
  • ▲
    DirectorExecutives
    1M HKD11HKEX
    151,000 shares@ HK$6.99174.6% of flowShareXHKGHKEX:DA20171012E00157
    Canonical exit: 8 Jan 2018 (T+90)
  • ▲
    DirectorExecutives
    483,000 HKD11HKEX
    69,000 shares@ HK$7.002.1% of flowShareXHKGHKEX:DA20171011E00165
    Canonical exit: 7 Jan 2018 (T+90)
  • ▲
    DirectorExecutives
    5M HKD13HKEX
    650,000 shares@ HK$6.96919.8% of flowShareXHKGHKEX:DA20171009E00188
    Canonical exit: 4 Jan 2018 (T+90)
  • ▲
    DirectorExecutives
    6M HKD16HKEX
    893,000 shares@ HK$6.99753.3% of flowShareXHKGHKEX:DA20170915E00011
    Canonical exit: 13 Dec 2017 (T+90)
  • ▲
    DirectorExecutives
    3M HKD13HKEX
    363,000 shares@ HK$6.997421.7% of flowShareXHKGHKEX:DA20170915E00010
    Canonical exit: 12 Dec 2017 (T+90)
  • ▲
    DirectorExecutives
    279,200 HKD11HKEX
    40,000 shares@ HK$6.982.4% of flowShareXHKGHKEX:DA20170914E00005
    Canonical exit: 11 Dec 2017 (T+90)
  • ▲
    DirectorExecutives
    3M HKD13HKEX
    380,000 shares@ HK$6.970922.5% of flowShareXHKGHKEX:DA20170914E00004
    Canonical exit: 10 Dec 2017 (T+90)

22 of 22 declarations

About China Shineway Pharmaceutical Group Ltd.

China Shineway Pharmaceutical Group Ltd. is a China-based pharmaceutical company engaged in the research, development, and manufacturing of pharmaceutical products. It is listed on the Hong Kong Stock Exchange.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations